Arax Advisory Partners’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$771K Buy
+11,012
New +$570K 0.01% 1356
2026
Q1
Sell
-274
Closed -$8.08K 4140
2025
Q4
$8.08K Buy
+274
New +$7.44K ﹤0.01% 2587
2025
Q3
Sell
-51
Closed -$1.41K 4054
2025
Q2
$1.41K Sell
51
-8
-14% -$211 ﹤0.01% 2669
2025
Q1
$1.67K Sell
59
-262
-82% -$9.3K ﹤0.01% 2122
2024
Q4
$13.3K Buy
321
+219
+215% +$10.5K ﹤0.01% 1377
2024
Q3
$6.82K Hold
102
﹤0.01% 1574
2024
Q2
$12.1K Sell
102
-198
-66% -$25.1K ﹤0.01% 1174
2024
Q1
$32K Buy
+300
New +$30.2K ﹤0.01% 579
2021
Q3
Sell
-500
Closed -$117K 1048
2021
Q2
$117K Buy
+500
New +$89.4K 0.02% 306

Other funds holding MRNA

Arax Advisory Partners's MRNA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Moderna (MRNA) in Q2 2026: 11,012 shares worth $771K. The stake represents 0.01% of the portfolio and ranks #1356 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MRNA as recently as Q4 2025.

Arax Advisory Partners first reported a position in MRNA in Q2 2021 and has held it in 9 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Arax Advisory Partners held 11,012 shares of Moderna worth $771K as of Q2 2026.
  • Moderna was a new Arax Advisory Partners position in Q2 2026.
  • Moderna made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1356 holding.
  • Arax Advisory Partners first reported a position in Moderna in Q2 2021 and has held it in 9 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.